Objective: Familial hypertrophic cardiomyopathy (FHC) due to mutations of cardiac troponin T (cTnT) is associated with a high frequency of sudden death even in the absence of cardiac hypertrophy. To investigate the causal relationship of cTnT mutations and this particular phenotype, we sought to establish a transgenic rat model for the disease. Methods: Transgenic rats were generated expressing human wild-type cTnT or two truncated cTnT molecules (del ex16, del ex15 / 16), resulting from an intron 15 splice donor site mutation previously observed in FHC patients. Transgenic rat hearts were characterized by histology, immunohistochemistry and in the 'working heart'. Results: Human wild-type and del ex16 cTnT were stably expressed and incorporated into the sarcomere of transgenic cardiomyocytes. Del ex16 transgenic rats revealed a lower level of expression (4-5%) than human wt cTnT animals (25-40%). In the 'working heart' model del ex16 hearts exhibited significant systolic and diastolic dysfunction without cardiac hypertrophy. In contrast, human wt cTnT hearts showed improved contractile performance and moderate myocardial hypertrophy. After 6 months of daily physical exercise one del ex16 rat died suddenly and three out of five del ex16 hearts revealed ventricular tachycardia / fibrillation. No arrhythmia was observed in human wt cTnT expressors. Myofibrillar disarray was present in del ex16 hearts after training but not in human wild-type cTnT rats or non-transgenic controls. Conclusion: A human cTnT deletion overexpressed in transgenic rats exerts a dominant-negative effect and mimics the phenotype of FHC with diastolic dysfunction and arrhythmias. By contrast, human cTnT wild-type animals reveal a gain of function and cardiac hypertrophy without arrhythmias.
effect, i.e. the mutated protein acts as a 'poison peptide', 2.2. Transient transfection of cos-cells interfering with the function of other sarcomeric proteins, 6 or (2) a stoichiometrical imbalance of the sarcomeric Cos-7 cells (10 ) were transfected with 15 mg of pSVL proteins due to failure to incorporate the mutant proteins in plasmid, containing wild-type or mutated cTnT, using a a regular manner (haplo-insufficiency).
modified calcium phosphate transfection protocol (MBS Missense mutations in the MHC-molecule seem to act in Transfection Kit, Stratagene). Cells were harvested after 72 a dominant-negative fashion. Expression of these mutant h. Western blot analysis was performed as described below, proteins in vitro [14] [15] [16] and in transgenic mice [17, 18] employing cTnT antibody 1B10. alter the regular function and structure of the sarcomere. Similar findings were reported for a human cTnT mutation (Arg92Gln), that caused contractile dysfunction in trans-2.3. Microinjection constructs fected cardiomyocytes in vitro [19] and in vivo [20] . In contrast, haplo-insufficiency was proposed in case of a
The human cTnT constructs were under the control of G→A splice-donor-site mutation of cTnT (Int15 ) [2] , leading the 2.1-kb myosin light chain-2 (mlc-2) promoter [25] . At to two truncated cTnT molecules. This view is supported the 39-end the SV40 untranslated region (EcoNI / SalI) of by analogy to a Drosophila troponin T deletion mutation the pGL2 vector (Promega, USA) was introduced via NotI. (upheld2) that acts as a null allele without detectable
At the 59-end of the mlc-2 promoter an oligonucleotide sarcomeric cTnT and loss of thin filaments in mutant containing an EcoRV and NotI-site was inserted via KpnI. muscle [21] . However, cardiac dysfunction was observed
The new NotI-site was used for introduction of the 2590 / in a mouse model expressing one of the cTnT deletion 91bp fragment of the human cytomegalovirus (CMV) mutations [22] . Our aim therefore was to extend the insight immediate-early enhancer in order to enhance expression into the pathomechanism of cTnT-FHC by establishing a levels [26] . The CMV enhancer fragment was generated by transgenic rat model expressing two human cTnT deletion PCR (template: CMV-b vector (Clontech, USA), primers: mutations (i) lacking exon 16 (ii) lacking exon 15 and 16 FCMV: CTATGCGGCCGCCGCTTCGAGCTCGCCCGand a wild-type human cTnT.
ACATTGATTATTGACTAGT and RCMV: CTATGC-GGCCGCATGGGGCGGAGTT GTTACGACATTTTGG-AAAGT). CTnT cDNAs were introduced via EcoRI after digestion of pSVL-cTnT with EcoRI. The final microin-2. Methods jection constructs were linearized by restriction with BssHII yielding a fragment of 4.9 kb. Correct sequence of 2.1. PCR -mutagenesis and vectors the constructs was confirmed by an automated sequencing device of Applied Biosystems (model 373A) (Medigene, Mutated cTnT cDNAs were generated by site-directed Germany). PCR-mutagenesis [23] using wild-type cTnT [24] as template [EcoRI-subcloned in Bluescript KS vector (Stratagene, La Jolla, CA, USA)]. The cTnT intron 15 2.4. Generation and analysis of transgenic rats splice-donor site mutation [2] led to the transcription of two deletion mutations (Fig. 1a) : Activation of a cryptic Microinjection constructs ( Fig. 2a) were purified as splice donor site in intron 15 results in premature terminapreviously described [24] and microinjected into male tion and the loss of the terminal 14 amino acid residues pronuclei of fertilized Sprague-Dawley rat oozytes [27] . (del ex16). Skipping of exon 15 leads to the loss of the DNA was extracted from rat tail biopsies with the Quiamp terminal 28 amino acids. Due to a frameshift seven new tissue kit (Qiagen, Germany). Heterozygote and homoresidues are encoded and a premature termination occurs zygote transgenic offspring was identified with PCR (del ex15 / 16).
(primers: MLCF3: GCAGGGGCCGGCCAGCAGGCTC Del ex16: primers F366(GGAGCTCGTTTCTCTC) / and R412:GCTCTGCCCGACGTCTCTCGAT CC) and R849(CCGCGGGTCTTGGAATGATCA GACTTTCTGSouthern blotting according to the protocol of the DIG GTTATCGTT) and F819(CGATAACCAGAAAGTCTGluminescent detection kit (Roche Diagnostics, Germany). ATCATCCAAGAC CCGCGGG) / R912(GAGGAGCAG-ATCTTTGG). Del ex15 / 16: primers F366 / R853(CCTT-CCCGCGGGTCTTGGAGCTCATATTTTCTGCTGCT-2.5. Protein analysis and Western blot TG) and F834(CTCCAAGACCCGCGG GAAGG) / R912. Wild-type cTnT was cloned (XhoI / BamHI) into expresRat tissue was immediately harvested and prepared sion vector pSVL (Pharmacia, Sweden). Mutated cTnT according to the Trizol-protocol (Gibco Life Technologies, PCR-products were also subcloned (del ex15 / 16: BalI / Germany). Protein concentration was determined with the BglII; del ex 16: SacI / BglII) into this vector for subprotein assay ESL (Roche Diagnostics). A 2.5-5 mg sequent in vitro transfection studies.
aliquot of total protein homogenate was separated by a 10% SDS-PAGE using a 2.5-5% stacking gel and (PBS). Primary antibodies (monoclonal anti-cardiac semidry blotted onto a nitrocellulose membrane. Detection troponin I 4B7 [31] , monoclonal anti-troponin T (1B10), of primary antibodies was carried out with the ECL-kit polyclonal anti-troponin T (SA4157)) and secondary anti-(Amersham, UK) using peroxidase-labeled secondary antibodies [Cy3-conjugated goat anti-mouse IgG and goat bodies against mouse and rabbit IgG, respectively, accordanti-rabbit IgG (Dianova, Germany)] were incubated in a ing to the manufacturers' protocol. The following antihumidified chamber at 378C for 60 min. Preparations were cTnT antibodies were used: (i) SA4157 (rabbit polyclonal visualized using a confocal microscope (MRC 500, Bioanti-cTnT antibodies, obtained after immunization with a Rad). human-specific cTnT peptide (NH -EEQEEAAEE-2 DAEAEA-COOH); (ii) monoclonal non-species specific 2.8. Isolated working heart perfusions cTnT antibodies 1B10 [28] and 1H10 [29] ; (iii) monoclonal human specific anti-cTnT antibody 2D10 (Research Myocardial function was evaluated using a modified Diagnostics, USA). Protein concentration on Western Blot isolated working heart preparation [32] . Animals were was estimated by densitometrical analysis (Molecular anesthetized with pentobarbital sodium (40 mg / kg i.p.). Analyst, Bio-Rad, Germany) using purified human cTnT After thoracotomy the aorta was cannulated and retrograde as standard (Biogenesis, UK).
aortic perfusion was initiated in situ to prevent ischemia. Hearts were than rapidly excised, mounted on a perfusion 2.6. Preparation of isolated neonatal rat cardiomyocytes apparatus (Hugo Sachs Elektronik (HSE), Germany) and perfused in a retrograde Langendorff mode with KrebsPrimary rat neonatal cardiomyocytes were prepared as Henseleit buffer [33] . The buffer was equilibrated at 378C described [30] Langendorff perfusion, the hearts were switched to the min with 3.7% formaldehyde. Cells were then permeabilworking heart mode with a defined preload of 10 mmHg ized using 0.4% Triton X-100 in phosphate buffered saline and afterload of 80 mmHg. Hearts were electrically paced In the upper blots a human-specific antibody against cTnT (2D10) was used detecting only transgenic human wild-type cTnT (hcTnT) or truncated cTnT (del ex16). Endogenous cTnT was visualized by a non-species-specific antibody (lower blots). To facilitate densitometric quantification of transgene expression a positive control of 50 ng of recombinant human cTnT was used for standardization.
near the sinoatrial node at 300 beats / min. Data on 2.9. Histological analyses contractile performance were collected on-line at a sampling rate of 100 Hz with an electronic data acquisition After CO asphyxiation, hearts were immediately re-2 system (MacLab ADInstruments, USA). Parameters meamoved. Contaminating blood was washed of by PBS. sured were heart rate, aortic pressure, left ventricular Hearts were then fixed in 4% paraformaldehyde-PBS and systolic (LVSP) and diastolic pressure and the maximal later processed for paraffin embedding, sectioning and and minimal first derivatives of LVSP as a function of time microscopic analysis. Routine staining was performed with (1dP/dt and 2dP/dt). Ten sequential beats were averhematoxylin-eosin (HE). Individual myocyte width was aged for each measurement. The relaxation times (RT) quantified microscopically with a measurement scale RT and RT were determined from peak intraventricular (Zeiss, Germany A subset of transgenic and control rats was subjected to exercise. Animals (10-12 weeks old) underwent treadmill 3. Results exercise for 60 min daily for 6 months. The speed of the treadmill was increased stepwise over 4 weeks up to the 3.1. Expression of human cTnT deletion mutations in maximum velocity that was tolerated for 1 h (0.3 m / s).
cos-7 cells After the training program, hearts were excised and examined in the 'working heart' model.
To test whether the cTnT deletion mutations could be The investigation conforms with the Guide for the Care stably expressed in vitro, cos-7 cells were transiently and Use of Laboratory Animals published by the US transfected with human wt and mutated cTnT deletion National Institutes of Health (NIH Publication No. 85-23, constructs under control of the SV40 promoter (Fig. 1a) . A revised 1996).
Western blot (Fig. 1b) probed with an anti-human cTnT-antibody (1B10) revealed a band with higher electrotransgenic animals as well as in non-transgenic controls. phoretic mobility in case of the cTnT deletion mutations Using the anti-human specific antibody SA4157 ( Fig. 3D ex16 (Fig. 3E) , though staining was less intense corresponding to the lower expression level of the deletion 3.2. Generation of transgenic rats overexpressing human mutation (4-5%) compared to human wild-type cTnT cTnT deletion mutations (25-40%) . No specific staining of the sarcomere was observed in cardiomyocytes of non-transgenic controls. Microinjections were performed to obtain rat lines These data demonstrate that the human cTnT deletion del expressing cTnT deletion mutations found in FHC patients ex16 and human wild-type cTnT are incorporated into the (del ex16 and del ex15 / 16). To examine possible effects of sarcomere of transgenic rats. human cTnT in the rat background also a wt human cTnT (hcTnT) construct (Fig. 2a) was introduced. 3.5. Transgenic rats and cardiac hypertrophy Microinjection of the hcTnT construct into 114 oocytes resulted in four independent lines out of ten potential Analysis of the heart weight / body weight ratio and founders, two expressing the transgene. Microinjection of cardiomyocyte size in 12-14-and 30-38-week-old del the del ex16 construct in 61 oocytes led to three inex16 transgenic rats did not show significant cardiac dependent lines out of ten potential founders, two expresshypertrophy compared to non-transgenic controls (Table ing the deletion mutation. Five independent injections of 1). In contrast, transgenic rats overexpressing human wildthe del ex15 / 16 construct with a total of 363 oocytes did type cTnT displayed a significant increase in heart / body not result in viable offspring containing the transgene. A weight ratio at age of 12-14 (114%) and 30-38 weeks high frequency of resorptions and stillbirths was observed (111%) and also an increase of cardiomyocyte size suggesting a lethal effect of the del ex15 / 16 transgene.
(116%), indicating myocardial hypertrophy. Rats subjected to physical exercise also exhibited a significantly higher 3.3. Expression of the transgene heart to body weight ratio as compared to untrained controls (123% in transgenic rats expressing human wildTo detect the expression of the human cTnT transgene type cTnT, 119% in rats expressing truncated cTnT (del in rat a human-specific monoclonal anti-cTnT antibody ex16) and 118% in non-transgenic rats). Cardiomyocyte (2D10) was used. On Western blotting (Fig. 2b) both width was accordingly increased (19-20%) in all trained transgenes, human wild-type (hcTnT) and truncated (del animals compared to untrained controls (Table 1 ). ex16) cTnT were detected by the anti-human cTnT antibody. Endogenous rat cTnT was detected by the non-3.6. Del ex16 rats exhibit impaired systolic and diastolic species-specific antibody 1B10. Densitometric analysis of function Western blots using recombinant human cTnT as standard revealed an expression level of the truncated cTnT of To examine the functional consequences of mutated and |4-5% in relation to endogenous rat cTnT. Human wildwild-type cTnT expression in transgenic rats, isolated type cTnT was expressed on higher level of |25-40%.
hearts were analyzed by the working heart perfusion The total amount of cTnT expression was not different apparatus ( enhanced systolic and diastolic function: Time to peak pressure was significantly reduced by 24% and 1dP/ dt 3.4. Human cTnT is incorporated into the sarcomere of and 2dP/dt were increased by 24 and 26%, respectively. transgenic rats 3.7. Cardiac arrhythmias in del ex16 transgenic rats To test for incorporation of transgenic proteins into the after physical exercise contractile apparatus of neonatal rat cardiomyocytes, transgenic and non-transgenic controls were analyzed by im-
The arrhythmogenic potential of the cTnT deletion munostaining (Fig. 3) . The non-species-specific anti-cTnT mutation was tested in rats subjected to daily treadmill (1B10) antibody (Fig. 3A-C) and the anti-troponin I exercise in order to imitate triggering events observed in (4B7) antibody (Fig. 3G-I ) revealed a similar regular FHC patients [34] . None of four rats overexpressing staining of the sarcomeric structure in del ex16 and hcTnT human wild-type cTnT and none of five non-transgenic A regular sarcomeric staining pattern was found in both non-transgenic controls and transgenic cardiomyocytes overexpressing the truncated (del ex 16) or human wild-type cTnT (hcTnT) using a non-species specific cTnT antibody (A-C) and an antibody against cardiac Troponin I (G-I). Immunostaining with a human cTnT-specific antiserum (SA4157) reveals a sarcomeric staining pattern in transgenic cardiomyocytes overexpressing the truncated human cTnT (E) and human wild-type cTnT (F) demonstrating incorporation of the transgenic proteins into the sarcomere. In contrast, endogenous rat cTnT was not visualized by the human specific antibody (D).
controls died suddenly or revealed any arrhythmia in the fibrillation in the working heart model. Animals not working heart apparatus (Fig. 5) . In contrast, one del ex16 subjected to exercise revealed neither arrhythmias in the transgenic animal died suddenly after exercise. Further-'working heart' nor died suddenly. more, the hearts of three out of five del ex16 transgenic animals exhibited ventricular tachycardia or ventricular 3.8. Histological analysis Table 1 Histological tissue sections of untrained transgenic or a Parameters of cardiac hypertrophy in transgenic rats non-transgenic rat hearts revealed no significant disarray or fibrosis (Fig. 6 ). However, 6 months after physical exerNon-tg del ex16 hcTnT cise transgenic rats expressing the del ex16 mutation (a) Heart weight / body weight ratio (3100)
showed areas of focal disarray (less than 5% of total FHC, the molecular mechanisms by which a specific and control animals were analyzed by immunofluorescence. Using a human cardiac cTnT-specific antibody 4.1. Expression and incorporation of the transgenes into sarcomeric cross-striation was only visible in carthe sarcomere diomyocytes of transgenic rats demonstrating integration of both human wild-type and truncated cTnT transgenes In the del ex16 transgenic rats expression of the into the sarcomere. These data further indicate a dominanttruncated human cTnT molecule was 4% compared to negative effect of mutated cTnT in vivo. wild-type rat cTnT. This low level of transgene expression is in accordance with other mouse models of FHC [18, 20, 22] . Low transgene expression is obviously suffi-4.2. Mutated human cTnT leads to diastolic dysfunction cient to induce cardiomyopathy, suggesting a dominantand arrhythmias negative effect of the truncated cTnT protein. It is tempting to speculate that a 'self-protective' mechanism exists that In patients with FHC, diastolic dysfunction is invariably differentially down-regulates the expression of the mutated found [36] , while end systolic volumes are markedly allele, since wild-type human cTnT was expressed in reduced due to a 'hypercontractile' left ventricle. These transgenic rats on an almost 10-fold higher level (25-40% clinical findings are largely explained by an increase of left of rat cTnT) whereas the copy numbers of the transgenes ventricular muscle mass and secondary fibrosis. In our were in the same range (3-5, data not shown). This transgenic rats carrying the cTnT deletion mutation diashypothesis on downregulation of the mutated allele is tolic dysfunction was clearly present as indicated by a further supported by an in vitro transfection study [35] . In significant prolongation of relaxation half time (RT : 50 this study the mutated cTnT was only 8% relative to 143%). In addition, there was evidence of systolic endogenous cTnT compared to 35% when wild-type cTnT dysfunction indicated by a significant decrease of time to was transfected. However, the differential expression peak pressure (TTP: 239%). Interestingly, the functional levels of mutated and wild-type cTnT could also be abnormalities in the working heart model were present without relevant myocardial hypertrophy or fibrosis. These the mutant protein and cannot solely be explained by findings not only correspond to clinical data but also match secondary effects of hypertrophy and fibrosis. previous in vitro data on isolated cardiomyocytes or
The cTnT intron 15 splice-donor mutation leads to two muscle strips, where systolic and diastolic dysfunction different aberrant splice products either lacking exon 15 cannot be attributed to secondary fibrosis [15, 19] . In other and 16 (plus seven nonsense amino acids) or a splice form studies mutated proteins were found to be incorporated only lacking exon 16. We therefore sought to establish into the sarcomere without major structural changes but transgenic lines for both truncations. In contrast to the still obvious contractile dysfunction [37, 38] . Similar obabove-mentioned mouse model [22] we established transservations were made in transgenic mouse models, where genic rats overexpressing the longer truncation (del ex16). introduction of an a-MHC mutation into the mouse Several attempts to obtain viable transgenic offspring genome [17] or expression of a cTnT missense mutation overexpressing the second cTnT deletion mutation (del [20] also led to diastolic dysfunction without significant ex15 / 16) (Fig. 1) were unsuccessful. A high frequency of cardiac hypertrophy. In a mouse model expressing the resorption and stillbirths was observed suggesting a lethal cTnT deletion mutation del ex15 / 16 diastolic dysfunction phenotype in the presence of cTnT protein lacking two was even present in a 'hypotrophic phenotype' with a exons. A lethal effect of del ex15 / 16 might be explained reduced heart-to-body weight ratio [22] . It is therefore by the high transcriptional activity of the mlc-2 promoter highly likely that diastolic dysfunction seen in FHC during the embryonic period [25] , which may have led to a patients is primarily due to the dominant-negative effect of toxic level of the transgene. In a transgenic mouse model Fig. 6 . Histological analyses of trained and untrained rat hearts. Rat hearts overexpressing the deletion mutation (del ex16) displayed myofibrillar disarray only after a 6-month course of physical exercise. In contrast, no disarray was observed in hearts of untrained del ex16 rats, non-transgenic controls, and transgenic rats expressing human wild-type cTnT irrespective of physical exercise. Sections of paraffin-embedded hearts were stained with HE (1003).
overexpressing del ex15 / 16 under control of the a-MHC cardiomyopathy on the molecular level is still poorly promoter viable heterozygous offspring was observed, understood. A carboxyterminal deletion might alter the whereas homozygous animals died soon after birth [22] .
interaction with either a-tropomyosin or troponin I and This might also be explained by a gene dosage effect due troponin C or both, which all bind to the C-terminus of the to the large increase of transcriptional activity of the troponin T molecule [42] . Furthermore, the cTnT truncaa-MHC promoter after birth [39] . It can therefore be tion leads to the deletion of a phosphorylation site of speculated that cTnT lacking both exons 15 and 16 possible importance for the regulation of ATPase activity exhibits a stronger dominant-negative effect compared to [43] . cTnT lacking only exon 16. Interestingly, it was recently A recently published in vitro study of several cTnT reported [40] that both truncations confer a higher calcium mutations in transfected quail myotubes found a reduction sensitivity increasing the Ca-activated force generation in of maximal force but an increased unloaded shortening vitro. Since at present it is unknown which deletion velocity [44] . The authors concluded that a shortened mutation predominates in the myocardium of FHC patients cross-bridge duty cycle may lead to increased energy carrying the intron 15 mutation it is important to establish demands of the myocardium, possibly resulting in energy that the longer cTnT-truncation also leads to contractile depletion at higher levels of cardiac work. This hypothesis dysfunction.
provides an explanation for typical features of cTnT Most cTnT mutations in FHC are associated with a high associated FHC such as diastolic dysfunction and a high incidence of sudden death although little or no hypertrophy incidence of malignant arrhythmias even in the absence of is found [9, 10] . Since it is established that arrhythmic significant hypertrophy. death in FHC patients frequently occurs on exertion [41] , we subjected transgenic and control rats to daily physical exercise. In the group carrying the cTnT deletion sudden 4.3. Overexpression of wild-type cTnT leads to a gain of death and severe ventricular arrhythmias during the workfunction ing heart performance were observed. Interestingly, focal myocardial disarray was only present in trained rats
The findings in the transgenic rats overexpressing expressing the deletion mutation possibly acting as the human wild-type cTnT were clearly different to those arrhythmogenic substrate. The arrhythmogenic potential of observed in rats overexpressing truncated human cTnT. the cTnT deletion mutation resembles the phenotype of First, a higher expression level (25-40% of endogenous rat human FHC.
cTnT) was observed in wild-type human cTnT rats. The precise mechanism how these cTnT mutations cause Secondly, there was a moderate but significant increase in heart to body weight ratio of 14% in 12-14-week-old and Acknowledgements of 11% in 30-38-week-old rats. Thirdly, a markedly improved systolic and diastolic function was found with a
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Fourthly, no arrhythmias were observed in hearts of human gemeinschaft to H.A.K. (493 / 3-1) and W.F. (SFB 320 / Bwild-type cTnT transgenic rats subjected to physical 6). training.
Thus, in contrast to rats expressing the truncated cTnT molecule, overexpression of human wild-type cTnT leads References to myocardial hypertrophy and improved contractile performance without an increased incidence of arrhythmias. increase of total cTnT mass could be observed. These expressing a myosin binding protein c deletion [45] . In this variations between rat and human cTnT exist at the amino- ment activation [42] . Recently it could be shown that 
